Šalis: Izraelis
kalba: anglų
Šaltinis: Ministry of Health
EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL AS FUMARATE
ABIC MARKETING LTD, ISRAEL
J05AR06
FILM COATED TABLETS
EFAVIRENZ 600 MG; EMTRICITABINE 200 MG; TENOFOVIR DISOPROXIL AS FUMARATE 245 MG
PER OS
Required
TEVA PHARMACEUTICAL INDUSTRIES LTD, ISRAEL
EMTRICITABINE, TENOFOVIR DISOPROXIL AND EFAVIRENZ
TRI-TEVA is indicated for use alone as a complete regimen or in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults.
2020-01-16
PATIENT LEAFLET IN ACCORDANCE WITH THE PHARMACISTS’ REGULATIONS (PREPARATIONS) – 1986 The medicine is dispensed with a doctor’s prescription only TRI-TEVA Coated tablets COMPOSITION: Active ingredients: Each coated tablet contains: Efavirenz 600 mg Emtricitabine 200 mg Tenofovir disoproxil (fumarate) 245 mg For information regarding inactive ingredients, see section 2 “Important information about some ingredients of the medicine” and section 6 “Additional information”. READ THE ENTIRE LEAFLET CAREFULLY BEFORE USING THE MEDICINE. This leaflet contains concise information about the medicine. If you have additional questions, refer to the doctor or the pharmacist. This medicine has been prescribed for you. Do not pass it on to others. It may harm them even if it seems to you that their medical condition is similar. Tri-Teva is intended for use by adults, from 18 years old and older. The medicine has not been studied in children under 18 years of age or in adults above 65 years of age. 1. WHAT IS THE MEDICINE INTENDED FOR? Tri-Teva can be used by itself as a full treatment, or in combination with other antiretroviral medicines, for treatment of HIV-1 infection in adults. The HIV virus destroys CD4+ T cells, which are important for the immune system. The immune system helps fighting infections. After a large number of T cells is destroyed, an Acquired Immune Deficiency Syndrome (AIDS) develops. Tri-Teva helps to block the HIV-1 reverse transcriptase enzyme, which is a viral chemical that is found in the body and is required for the multiplication of HIV-1. Tri-Teva reduces the amount of HIV-1 in the blood (viral load). Tri-Teva may also help increase the number of T cells (CD4+ cells), thereby improving the function of the immune system. Reducing the amount of HIV-1 in the blood reduces the risk for death or for infections that occur when the immune system is weak (opportunistic infections). Tri-Teva does not cure a HIV-1 infection or AIDS, and you may continue to experience illnesses that are related to Perskaitykite visą dokumentą